FLT3 tyrosine kinase inhibitor, midostaurin (PKC412), is tested in phase 1 and 2 clinical study for acute myeloid leukemia in combination with HDM-201 (NCT03760445). Here, FLT3 is linked to acute myeloid leukemia.